actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
This process is referred to as acclimatization: the maximum rate of sweating increases and its solute composition decreases. The volume of water lost in sweat daily is highly variable, ranging from 100 to 8,000 millilitres per day (0.041 to 3.259 imp fl oz/ks). The solute loss can be as much as 350 mmol/d (or 90 mmol/d acclimatised) of sodium under the most extreme conditions. During average intensity exercise, sweat losses can average up to 2 litres (0.44 imp gal; 0.53 US gal) of water/hour. In a cool climate and in the absence of exercise, sodium loss can be very low (less than 5 mmol/d). Sodium concentration in sweat is 30–65 mmol/L, depending on the degree of acclimatisation. Horses have a thick, waterproofed, hairy coat that would normally block the rapid translocation of sweat water from the skin to the surface of the hair required for evaporative cooling. To solve this, horses have evolved a detergent-like protein, latherin, that they release at high concentrations in their sweat. Their perspiration unlike humans is created by apocrine glands. This protein, by wetting the horses' coat hairs facilitate water flow for cooling evaporation. The presence of this protein can be seen in the lathering that often occurs on the coats of sweating horses, especially when rubbed. In hot conditions, horses during three hours of moderate-intensity exercise can lose 30 to 35 litres (6.6 to 7.7 imp gal; 7.9 to 9.2 US gal) of water and 100 grams (3.5 oz) of sodium, 198 grams (7.0 oz) of chloride and 45 grams (1.6 oz) of potassium.
Small amounts of melamine have also been reported in foodstuff as a metabolite product of cyromazine, an insecticide used on animals and crops. The Food Safety and Inspection Service (FSIS) of the United States Department of Agriculture (USDA) provides a test method for analyzing cyromazine and melamine in animal tissues. In 2007, the FDA began using a high performance liquid chromatography test to determine the melamine, ammeline, ammelide, and cyanuric acid contamination in food. Another procedure is based on surface-enhanced Raman spectroscopy (SERS). Member states of the European Union are required under Commission Decision 2008/757/EC to ensure that all composite products containing at least 15% of milk product, originating from China, are systematically tested before import into the Community and that all such products which are shown to contain melamine in excess of 2.5 mg/kg are immediately destroyed. Following the 2008 melamine milk scandal, China restructured its food safety system by implementing the Food Safety Law, introducing stricter dairy industry regulations, and establishing independent third-party inspections to strengthen oversight and restore public trust. The 2009 Food Safety Law also reorganized government oversight by placing food safety regulation under a uniform national framework that employs risk-based standards and adheres to international Codex Alimentarius Commission guidelines.
The town has a large Chalcolithic deposit, one of the largest of Spain. In Valencina there are two very famous dolmens, the dolmen of Matarrubilla and the Dolmen de la Pastora. A dolmen is a megalithic tomb with several upright stones supporting a flat table or capstone. Many date back to pre 3000 BC. Originally the dolmens were covered with earth to form a barrow, but time has eroded the soil leaving just the stones over the graves intact. Two tombs in the area have contributed to a significant find in archaeological research. An elaborate tomb with rich artifacts (the Tholos de Montelirio) determined to be that of the cultural leader who, evidence indicates was venerated for decades after burial and another tomb that was not so elaborate, but also with artifacts that indicate high social status as a leader, had been excavated in Valencina and studied extensively. In 2023, a dental enamel analysis technique that enables precise gender identification facilitated reinterpretation of the finds. The new scientific analysis revealed that both tombs belonged to women and this evidence has led to a complete reassessment of the culture and perhaps, to many finds where accurate gender identification had not been possible previously and had led to presumptions about the cultures now being shown as incorrect.
Sources: en.wikipedia.org
== Genetics and diseases == Hemoglobin D is synthesised due to mutation in HBB, the gene that produces β-subunits of hemoglobin and is present on human chromosome 11. A point mutation in the first base of the 121 codon that normally has GAA sequence for normal hemoglobin is changed to CAA. GAA codes for glutamic acid, while CAA for glutamine. This gene mutation makes HbD, which can further give rise to several genetic and disease conditions. The specific mutations can occur at different sites of the gene. According to the Globin Gene Server database, there are other types of HbD such as HbD-Agri (HBB:c.29C→A;364G→C), HbD-Bushman (HBB:c.49G→C), HbD-Ouled Rabah (HBB:c.60C→A or 60C→G), HbD-Iran (HBB:c.67G→C), HbD-Granada (HBB:c.68A→T), HbD-Ibadan (HBB:c.263C→A) and HbD-Neath (HBB:c.365A→C). Depending on the nature of inheritance of HbD mutation there are four conditions, some of which can be deadly diseases:
When diagnosed with myasthenia gravis, an individual can be stratified into distinct subgroups based on the clinical features and serological status, e.g., affected muscle group, age of onset, thymic abnormalities, and profile of serum autoantibodies. Based on the affected muscle group, people with myasthenia gravis can be sub-grouped into ocular myasthenia gravis or generalized myasthenia gravis. Ocular myasthenia gravis is characterized by exclusively ocular symptoms, droopy eyelids, or double vision. Generalized myasthenia gravis has muscle weakness with a variable combination of the bulbar, axial, or limb and respiratory muscles. People with myasthenia gravis can also be sub-grouped by the age of onset: juvenile-onset myasthenia gravis (onset age ≤ 18 years of age), early-onset MG (EOMG; 19–50 years of age), late-onset MG (LOMG; onset > 50 years of age), and very late-onset (VLOMG; onset age ≥ 65 years of age). The subgroup of the autoantibody profile includes AChR seropositive, MuSK seropositive, LRP4 seropositive, and agrin seropositive.
==== 500–599 ==== Water Supply and Sewerage Services (Customer Service Standards) (Amendment) Regulations 1993 (S.I. 1993/500) Local Government Finance Act 1992 (Community Charge Benefits) Saving Order 1993 (S.I. 1993/502) Bovine Animals (Identification, Marking and Breeding Records) (Amendment) Order 1993 (S.I. 1993/503) Prisoner Escorts Rules 1993 (S.I. 1993/515) Prison (Amendment) Rules 1993 (S.I. 1993/516) Common Agricultural Policy (Wine) Regulations 1993 (S.I. 1993/517) Social Security Benefits (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/518) Occupational and Personal Pension Schemes (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/519) Local Authorities (Capital Finance) (Amendment) Regulations 1993 (S.I. 1993/520) National Health Service (General Medical and Pharmaceutical Services) (Scotland) Amendment Regulations 1993 (S.I. 1993/521) National Health Service (Charges for Drugs and Appliances) (Scotland) Amendment Regulations 1993 (S.I. 1993/522) National Health Service (Dental Services) (Miscellaneous Amendments) (Scotland) Regulations 1993 (S.I. 1993/523) National Health Service (Optical Charges and Payments) (Scotland) Amendment Regulations 1993 (S.I. 1993/524) Education (Fees and Awards) (Scotland) Amendment Regulations 1993 (S.I. 1993/525) Council Tax (Dwellings) (Scotland) Regulations 1993 (S.I. 1993/526) Council Tax (Transitional Reduction Scheme) (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/527) Legal Aid in Contempt of Court Proceedings (Scotland) Amendment Regulations 1993 (S.I.
Sources: en.wikipedia.org
James Dell Talarico (né Collins; TAL-uh-REE-koh, born May 17, 1989) is an American politician, Presbyterian seminarian, and educator serving since 2018 as a member of the Texas House of Representatives. He is the Democratic Party's nominee in the 2026 U.S. Senate election in Texas. Born in Round Rock, Texas, Talarico graduated from the University of Texas at Austin with a Bachelor of Arts in government in 2011, and from Harvard University with a Master of Education degree in education policy in 2016. Before entering politics, Talarico was a middle school English teacher and an executive director for an education nonprofit. He is serving his fourth term in the Texas House of Representatives, having first been elected in 2018. While serving in the Texas House, Talarico started to pursue a Master of Divinity at Austin Presbyterian Theological Seminary. In 2025, he announced his candidacy for the United States Senate in 2026. He defeated U.S. representative Jasmine Crockett in the Democratic primary and will face the Republican nominee, Texas attorney general Ken Paxton, in the general election.
== Side effects == Possible side effects of cyanocobalamin injection include allergic reactions such as hives, difficult breathing; redness of the face; swelling of the arms, hands, feet, ankles or lower legs; extreme thirst; and diarrhea. Less-serious side effects may include headache, dizziness, leg pain, itching, or rash. Treatment of megaloblastic anemia with concurrent vitamin B12 deficiency using B12 vitamers (including cyanocobalamin), creates the possibility of hypokalemia due to increased erythropoiesis (red blood cell production) and consequent cellular uptake of potassium upon anemia resolution. When treated with cyanocobalamin, patients with Leber's disease may develop serious optic atrophy, possibly leading to blindness, based on few case reports.
=== CTFR screening === Depending on the severity of the hypospermia (volume ≤ 1 mL) a molecular study of the CFTR gene may be performed. This is done by a molecular "screening" method (high performance liquid chromatography under denaturing conditions (D-HPLC) followed by sequencing of the exons of interest, allowing to detect nearly 95% of mutations in this gene, and even discover new mutations. After this molecular screening step, if variants of the CFTR gene are detected, the geneticist will use computer databases to distinguish whether this nucleotide variant corresponds to a polymorphism of the CFTR gene (without consequence on the function of the CFTR protein) or to a real mutation.
== Veterinary use == Bicalutamide may be used to treat hyperandrogenism and associated benign prostatic hyperplasia secondary to hyperadrenocorticism (caused by excessive adrenal androgens) in male ferrets. However, it has not been formally assessed in controlled studies for this purpose.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.